rTMS for Adults With Autistic Spectrum Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2012 by Chang Gung Memorial Hospital
Sponsor:
Information provided by (Responsible Party):
Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01918787
First received: August 2, 2013
Last updated: August 7, 2013
Last verified: April 2012
  Purpose

rTMS over dorsolateral prefrontal cortex is effective in reducing repetitive behaviors in adults with autistic spectrum disorder rTMS over posterior superior temporal sulcus is effective in improving social ability in adults with autistic spectrum disorder


Condition Intervention Phase
Autism
Device: repetitive TMS
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Examine the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Symptoms of Autism Spectrum Disorder

Resource links provided by NLM:


Further study details as provided by Chang Gung Memorial Hospital:

Primary Outcome Measures:
  • continuous performance test [ Time Frame: continuous performance test will be arranged before and after rTMS within one hour ] [ Designated as safety issue: No ]
    continuous performance test will be arranged before and after rTMS within one hour


Secondary Outcome Measures:
  • Yale-Brown Obsessive Compulsive Scale [ Time Frame: Yale-Brown Obsessive Compulsive Scale will be evaluated before and after rTMS within one week ] [ Designated as safety issue: No ]
    Yale-Brown Obsessive Compulsive Scale will be evaluated before and after rTMS. The time point of evaluation is before rTMS, one hour after rTMS, 3 days after rTMS and one week after rTMS.


Other Outcome Measures:
  • Autism Spectrum Quotient [ Time Frame: Autism Spectrum Quotient will be evaluated before and after rTMS within one week ] [ Designated as safety issue: No ]
    Autism Spectrum Quotient will be evaluated before and after rTMS. The time point of evaluation is before rTMS, one hour after rTMS, 3 days after rTMS and one week after rTMS.


Estimated Enrollment: 30
Study Start Date: April 2012
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: repetitive TMS
repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
Device: repetitive TMS
rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control

Detailed Description:

First, we will apply one session intermittent theta burst stimulation over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control with one week interval in adults with autism spectrum disorder. Second, we will apply 5 sessions intermittent theta burst stimulation within one week over dorsolateral prefrontal cortex or posterior temporal sulcus depending on the results of our first phases.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults with autistic spectrum disorder

Exclusion Criteria:

  • schizophrenia
  • bipolar affective disorder
  • major depressive disorder
  • any systemic disease especially epilepsy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01918787

Contacts
Contact: Hsing Chang Ni, MD 886-3-3281200 ext 2479 alanni0918@yahoo.com.tw

Locations
Taiwan
Chang Gung Memorial Hospital Recruiting
Taoyuan, Taiwan
Contact: Hsing Chang Ni    886-3-3281200 ext 2479    alanni0918@yahoo.com.tw   
Principal Investigator: Hsing Chang Ni, MD         
Sponsors and Collaborators
Chang Gung Memorial Hospital
Investigators
Principal Investigator: Hsing-Chang Ni, MD Chang Gung Memorial Hospital at Linkou, Taiwan
  More Information

No publications provided

Responsible Party: Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT01918787     History of Changes
Other Study ID Numbers: 100-2985C, NSC 100-2314-B-182A-075
Study First Received: August 2, 2013
Last Updated: August 7, 2013
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Mental Disorders Diagnosed in Childhood
Mental Disorders

ClinicalTrials.gov processed this record on July 23, 2014